Alpha Cognition Inc. (NASDAQ:ACOG – Get Free Report) COO Lauren D’angelo bought 3,500 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The shares were acquired at an average price of $5.76 per share, with a total value of $20,160.00. Following the transaction, the chief operating officer directly owned 140,695 shares of the company’s stock, valued at $810,403.20. This represents a 2.55% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Alpha Cognition Trading Up 0.9%
NASDAQ ACOG opened at $5.80 on Wednesday. Alpha Cognition Inc. has a 12 month low of $4.50 and a 12 month high of $11.54. The stock has a market cap of $126.27 million, a PE ratio of -4.30 and a beta of 2.38. The stock’s 50 day moving average is $6.07 and its 200 day moving average is $5.91.
Alpha Cognition (NASDAQ:ACOG – Get Free Report) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.04. Alpha Cognition had a negative net margin of 232.23% and a negative return on equity of 58.35%. The business had revenue of $3.53 million during the quarter, compared to analyst estimates of $3.42 million. On average, analysts forecast that Alpha Cognition Inc. will post -1.34 EPS for the current fiscal year.
Institutional Trading of Alpha Cognition
Analysts Set New Price Targets
Several research analysts have commented on ACOG shares. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Alpha Cognition in a report on Monday, April 27th. Craig Hallum started coverage on Alpha Cognition in a research report on Friday, April 17th. They issued a “buy” rating and a $14.00 target price on the stock. Finally, Wall Street Zen cut Alpha Cognition from a “hold” rating to a “sell” rating in a report on Saturday, May 2nd. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat, Alpha Cognition has a consensus rating of “Buy” and a consensus price target of $16.00.
Read Our Latest Analysis on ACOG
Alpha Cognition Company Profile
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Read More
- Five stocks we like better than Alpha Cognition
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
